Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot studyReport as inadecuate




Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study - Download this document for free, or read online. Document in PDF available to download.

Cardiovascular Diabetology

, 15:153

First Online: 04 November 2016Received: 23 August 2016Accepted: 26 October 2016

Abstract

BackgroundTrelagliptin, an oral DPP-4 inhibitor, which is administered once per week and characterized by a long half-life in blood. The effects of trelagliptin on vascular endothelial functions have not been clarified to date. The objective of the present study was to examine the effects of trelagliptin on vascular endothelial functions in patients with type 2 diabetes mellitus DM using flow-mediated dilatation FMD, adiponectin, and asymmetric dimethylarginine ADMA as evaluation indicators.

MethodsThis study was a preliminary single-arm prospective pilot study. The subjects of this study were type 2 DM patients aged 20–74 years, who visited our outpatient department. The patients were treated with trelagliptin, and their FMD, adiponectin, and ADMA levels were measured at baseline and at 12 weeks after initial treatment to determine the changes during the study period.

ResultsA total of 27 patients, excluding three dropouts, were included in the population for analysis. Trelagliptin treatment showed no significant changes in FMD 2.42 ± 2.7% at baseline vs. 2.66 ± 3.8% post-treatment, P = 0.785 and ADMA 0.41 ± 0.0 µg-mL at baseline vs. 0.40 ± 0.0 µg-mL post-treatment, P = 0.402. Trelagliptin treatment resulted in a significant increase of serum adiponectin level 7.72 ± 6.9 µg-mL at baseline vs. 8.82 ± 8.3 µg-mL post-treatment, P < 0.002.

ConclusionsIn this pilot study, trelagliptin treatment showed no significant changes in FMD. On the other hand, it was believed that trelagliptin treatment may increase serum adiponectin level.

Trial Registrationhttp:-www.umin.ac.jp Trial ID UMIN000018311

KeywordsType 2 diabetes mellitus Dipeptidyl peptidase-4 inhibitor Trelagliptin Vascular endothelial functions AbbreviationsDMdiabetes mellitus

FMDflow-mediated dilatation

ADMAasymmetric dimethylarginine

NOnitric oxide

DPP-4dipeptidyl peptidase-4

GLP-1glucagon-like peptide-1

CIMTcarotid intima media thickness

baPWVbrachial-ankle pulse wave velocity

HbA1chemoglobin A1c

BMIbody mass index

ASTaspartate aminotransaminase

ALTalanine aminotransferase

Ccrcreatinine clearance

IRIimmunoreactive insulin

HOMAhomeostasis model assessment

eGFRestimated glomerular filtration rate

LDLClow-density lipoprotein cholesterol

HDLChigh-density lipoprotein cholesterol

TGtriglycerides

ACRalbumin–creatinine ratio

Download fulltext PDF



Author: Satoshi Ida - Kazuya Murata - Katunori Betou - Chiaki Kobayashi - Yuki Ishihara - Kanako Imataka - Akihiro Uchida - Kou Mo

Source: https://link.springer.com/article/10.1186/s12933-016-0468-4







Related documents